Significance of Rosiglitazone Inhibiting TLR4 Expression in Partial Hepatic Ischemia/Reperfusion of Mice

The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor γ (PPARγ) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BABL/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. The model of the mouse partial hepatic ische- mia/reperfusion injury was established. All the animals were randomly divided into 3 groups: rosiglitazone group, vehicle (dimethylsulphoxide, DMSO) group and sham operation group. The hepatic samples were collected when mice were sacrificed 0, 2, 4 and 6 h after reperfusion following 1 h ischemia to analyze the acute phase of hepatic IRI. The dynamic expression of TlR4 mRNA was de- tected quantitatively by real-time-PCR, and the levels of TNF-α, IL-10 and ALT in portal vein were determined in all groups. After restoration of blood supply, the expression of TLR4 mRNA in ischemic lobes was detected in 0, 2, 4 and 6 h after reperfusion following 1 h ischemia in rosiglitazone group and vehicle group. The most intensive expression of TLR4 mRNA was present at 4 h after reperfusion in ischemic lobes in vehicle group. As compared with vehicle group, the expression of TLR4 mRNA in ischemic lobes in rosiglitazone group was significantly decreased at 4 h after reper- fusion. The level of IL-10 in portal vein was markedly up-regulated in rosiglitazone group as compared with vehicle group. Contrarily, the levels of TNF-α and ALT in portal vein were markedly down-regulated in rosiglitazone group as compared with vehicle group at every time point in mouse partial hepatic IRI model. Rosiglitazone could alleviate the hepatic IRI by inhibiting TLR4 receptor-mediated inherent immune response.     

肝切除术治疗肝内胆管结石

目的:探讨肝切除治疗肝内胆管结石的临床疗效分析。方法:回顾性分析肝部分切除术治疗原发性肝内胆管结石115例的临床资料,其中行左半肝切除术74例,左外叶切除术17例,左内叶切除术5例;右后叶切除术11例,右肝部分切除术6例,右半肝切除术2例。其中附加胆肠内引流术10例(8.70%)。结果:全组无术中及术后死亡,手术后发生并发症19例(16.52%),包括肝功能衰竭、胆漏、胆道出血、膈下脓肿、伤口感染、肺部感染、炎性肠梗阻等。94例获6个月～18年的随访,平均随访10.5年,优良率89.36%,结石复发10例,占8.70%。结论:肝切除是治疗肝内胆管结石最有效的方法,同时联合应用其他手术方式能明显提高治疗效果。     

肝内胆管结石再手术原因浅析

目的:探讨肝内胆管结石术后再手术原因.方法:对近11年胆管结石再手术的21例患者的临床资料进行回顾性分析.结果:再手术发现残留或复发结石的部位,肝内胆管结石6例,胆总管结石3例,肝内外胆管结石8例,胆肠Roux-en-Y吻合口狭窄并结石嵌顿1例,肝或胆总管空肠Roux-en-Y吻合口以上胆管狭窄梗阻2例,反流性胆管炎并肝内胆管结石1例.结论:选择正确手术方式、合适的手术时机、术者良好的手术经验技术和先进的设备及术后有效治疗是预防胆管结石再手术的重要因素.